Acrivon TherapeuticsACRV
Market Cap: $250M
About: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Employees: 61
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
243% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 7
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
25% more capital invested
Capital invested by funds: $109M [Q1] → $136M (+$26.9M) [Q2]
15% more funds holding
Funds holding: 47 [Q1] → 54 (+7) [Q2]
7.17% more ownership
Funds ownership: 68.78% [Q1] → 75.95% (+7.17%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 30 / 108 met price target | 172%upside $22 | Buy Reiterated | 13 Aug 2024 |